RT Journal Article
T1 Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER).
A1 Galindo-Izquierdo, María
A1 Rodriguez-Almaraz, Esther
A1 Pego-Reigosa, José M
A1 López-Longo, Francisco J
A1 Calvo-Alén, Jaime
A1 Olivé, Alejandro
A1 Fernández-Nebro, Antonio
A1 Martinez-Taboada, Víctor
A1 Vela-Casasempere, Paloma
A1 Freire, Mercedes
A1 Narváez, Francisco J
A1 Rosas, José
A1 Ibáñez-Barceló, Mónica
A1 Uriarte, Esther
A1 Tomero, Eva
A1 Zea, Antonio
A1 Horcada, Loreto
A1 Torrente, Vicenç
A1 Castellvi, Iván
A1 Calvet, Joan
A1 Menor-Almagro, Raúl
A1 Aguirre Zamorano, María A
A1 Raya, Enrique
A1 Díez-Álvarez, Elvira
A1 Vázquez-Rodríguez, Tomás
A1 García de la Peña, Paloma
A1 Movasat, Atusa
A1 Andreu, José L
A1 Richi, Patricia
A1 Marras, Carlos
A1 Montilla-Morales, Carlos
A1 Hernández-Cruz, Blanca
A1 Marenco de la Fuente, José L
A1 Gantes, María
A1 Úcar, Eduardo
A1 Alegre-Sancho, Juan J
A1 Manero, Javier
A1 Ibáñez-Ruán, Jesús
A1 Rodríguez-Gómez, Manuel
A1 Quevedo, Víctor
A1 Hernández-Beriaín, José
A1 Silva-Fernández, Lucía
A1 Alonso, Fernando
A1 Pérez, Sabina
A1 Rúa-Figueroa, Iñigo
K1 Nefritis lúpica
K1 Recurrencia
K1 Sistema de registro
K1 Estudios retrospectivos
K1 Reumatología
K1 España
AB The aim of the study was to profile those patients included in the RELESSER registry with histologically proven renal involvement in order to better understand the current state of lupus nephritis (LN) in Spain. RELESSER-TRANS is a multicenter cross-sectional registry with an analytical component. Information was collected from the medical records of patients with systemic lupus erythematosus who were followed at participating rheumatology units. A total of 359 variables including demographic data, clinical manifestations, disease activity, severity, comorbidities, LN outcome, treatments, and mortality were recorded. Only patients with a histological confirmation of LN were included. We performed a descriptive analysis, chi-square or Student's t tests according to the type of variable and its relationship with LN. Odds ratio and confidence intervals were calculated by using simple logistic regression. LN was histologically confirmed in 1092/3575 patients (30.5%). Most patients were female (85.7%), Caucasian (90.2%), and the mean age at LN diagnosis was 28.4 ± 12.7 years. The risk for LN development was higher in men (M/F:47.85/30.91%, P < 0.001), in younger individuals (P < 0.001), and in Hispanics (P = 0.03). Complete response to treatment was achieved in 68.3% of patients; 10.35% developed ESRD, which required a kidney transplant in 45% of such cases. The older the patient, the greater was the likelihood of complete response (P < 0.001). Recurrences were associated with persistent lupus activity at the time of the last visit (P < 0.001) and with ESRD (P < 0.001). Thrombotic microangiopathy was a risk factor for ESRD (P = 0.04), as for the necessity of dialysis (P = 0.01) or renal transplantation (P = 0.03). LN itself was a poor prognostic risk factor of mortality (OR 2.4 [1.81-3.22], P < 0.001). Patients receiving antimalarials had a significantly lower risk of developing LN (P < 0.001) and ESRD (P < 0.001), and responded better to specific treatments for LN (P = 0.014). More than two-thirds of the patients with LN from a wide European cohort achieved a complete response to treatment. The presence of positive anti-Sm antibodies was associated with a higher frequency of LN and a decreased rate of complete response to treatment. The use of antimalarials reduced both the risk of developing renal disease and its severity, and contributed to attaining a complete renal response.
PB Lippincott, Williams & Wilkins
SN 0025-7974
YR 2016
FD 2016-03
LK http://hdl.handle.net/10668/2402
UL http://hdl.handle.net/10668/2402
LA en
NO Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigosa JM, López-Longo FJ, Calvo-Alén J, Olivé A, et al. Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). Medicine (Baltimore). 2016 Mar; 95(9):e2891
NO Journal Article; Observational Study; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 11, 2025